Molecules involved in USP8/EGFR and TR4 signaling pathways as well as selective inhibitors of HSP90 are emerging as attractive therapeutic targets, especially as no ideal treatment exists for treating corticotroph adenomas not cured by surgery, possibly paving the way for personalized medicine in the future. The gene discussed is USP8; the disease is ACTH-producing pituitary gland adenoma.